260
Participants
Start Date
July 18, 2022
Primary Completion Date
October 24, 2022
Study Completion Date
March 24, 2023
aH5N6c on Day 1
MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 hemagglutinin (HA) (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume)
aH5N6c on Day 22
MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular (IM) administration, containing 7.5 μg H5N6 HA (A/Guangdong/18SF020/2018 (H5N6)-like) + 0.25 mL MF59 (approximately 0.5 mL total volume) given 3 weeks after the first aH5N6c vaccination
Placebo on Day 22
Saline placebo (sterile, 0.5 mL) given 3 weeks after the aH5N6c vaccination
Rochester Clinical Research, Inc, Rochester
AccellaCare, Winston-Salem
PMG Research of Raleigh, Raleigh
Optimal Research, LLC, Melbourne
Innovative Research of West Florida, Inc., Clearwater
Optimal Research, LLC, Huntsville
Aventiv Research, Columbus
Great Lakes Clinical Trials LLC, Chicago
Sundance Clinical Research, LLC, St Louis
The Center for Pharmaceutical Research, Kansas City
Heartland Research Associates, LLC, Wichita
Biogenics Research Institute, San Antonio
J. Lewis Research, Inc/Jordan River Family Medicine, South Jordan
J. Lewis Research, Inc/Foothill Family Clinic North, Salt Lake City
J. Lewis Research, Inc/Foothill Family Clinic South, Salt Lake City
Clinical Research Consortium Arizona, Tempe
California Research Foundation, San Diego
Clinical Research Consulting, LLC, Milford
Seqirus
INDUSTRY